The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease.
作者信息
Cronin Robert M, Lin Chyongchiou J, Chiang ChienWei, MacEwan Sarah R, DeBaun Michael R, Hyer J Madison
机构信息
Department of Internal Medicine, The Ohio State University, Columbus, OH.
College of Nursing, The Ohio State University, Columbus, OH.
出版信息
Blood Adv. 2023 Jul 11;7(13):3114-3116. doi: 10.1182/bloodadvances.2022008965.
Abstract
摘要
相似文献
1
The use of FDA-approved medications for preventing vaso-occlusive events in sickle cell disease.
Blood Adv. 2023 Jul 11;7(13):3114-3116. doi: 10.1182/bloodadvances.2022008965.
2
Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy.
Pediatr Blood Cancer. 2016 Feb;63(2):299-305. doi: 10.1002/pbc.25771. Epub 2015 Sep 24.
3
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events.
N Engl J Med. 2016 Feb 18;374(7):625-35. doi: 10.1056/NEJMoa1512021. Epub 2015 Dec 8.
4
Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease: A Randomized Clinical Trial.
JAMA. 2021 Apr 20;325(15):1513-1523. doi: 10.1001/jama.2021.3414.
5
Addressing challenges of clinical trials in acute pain: The Pain Management of Vaso-occlusive Crisis in Children and Young Adults with Sickle Cell Disease Study.
Clin Trials. 2016 Aug;13(4):409-16. doi: 10.1177/1740774516636573. Epub 2016 Mar 21.
6
Primary hyperparathyroidism mimicking vaso-occlusive crises in sickle cell disease.
Pediatrics. 2006 Aug;118(2):e537-9. doi: 10.1542/peds.2006-0337.
7
Systematic Review of l-glutamine for Prevention of Vaso-occlusive Pain Crisis in Patients with Sickle Cell Disease.
Pharmacotherapy. 2019 Nov;39(11):1095-1104. doi: 10.1002/phar.2329. Epub 2019 Oct 9.
8
Safe use of hydroxycarbamide in sickle cell disease patients hospitalized for painful vaso-occlusive episodes during the randomized, open-label HELPS study.
Br J Haematol. 2022 Oct;199(1):153-157. doi: 10.1111/bjh.18349. Epub 2022 Jul 14.
9
Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.
Cochrane Database Syst Rev. 2015 Dec 18;2015(12):CD010155. doi: 10.1002/14651858.CD010155.pub3.
10
The vaso-occlusive pain crisis in sickle cell disease: Definition, pathophysiology, and management.
Eur J Haematol. 2020 Sep;105(3):237-246. doi: 10.1111/ejh.13430. Epub 2020 May 19.
引用本文的文献
1
Virtual Reality as RESPITE: Relief Exploration for Sickle Pain Through Interventions Using Technology Engagement: A Hospital-Based Observational Study.
J Gen Intern Med. 2025 Aug 15. doi: 10.1007/s11606-025-09812-z.
2
Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease.
Blood. 2024 Mar 7;143(10):866-871. doi: 10.1182/blood.2023021167.
3
Comparing super-utilizers and lower-utilizers among commercial- and Medicare-insured adults with sickle cell disease.
Blood Adv. 2024 Jan 9;8(1):224-233. doi: 10.1182/bloodadvances.2023010813.
本文引用的文献
1
Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium.
PLoS One. 2021 Oct 29;16(10):e0258638. doi: 10.1371/journal.pone.0258638. eCollection 2021.
2
Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.
JAMA Netw Open. 2021 Oct 1;4(10):e2128971. doi: 10.1001/jamanetworkopen.2021.28971.
3
Age-related prescription medication utilization for the -management of sickle cell disease among Texas Medicaid patients.
J Opioid Manag. 2021 Jul-Aug;17(4):301-310. doi: 10.5055/jom.2021.0662.
4
Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research.
Pediatr Blood Cancer. 2020 Dec;67(12):e28703. doi: 10.1002/pbc.28703. Epub 2020 Sep 17.
5
Vaso-occlusive crises and costs of sickle cell disease in patients with commercial, Medicaid, and Medicare insurance - the perspective of private and public payers.
J Med Econ. 2020 Nov;23(11):1345-1355. doi: 10.1080/13696998.2020.1813144. Epub 2020 Sep 9.
6
Medical Resource Use and Costs of Treating Sickle Cell-related Vaso-occlusive Crisis Episodes: A Retrospective Claims Study.
J Health Econ Outcomes Res. 2020 Jun 15;7(1):52-60. doi: 10.36469/jheor.2020.12852. eCollection 2020.
7
Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Pediatrics. 2019 Jul;144(1). doi: 10.1542/peds.2018-3285.
8
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
9
A Phase 3 Trial of l-Glutamine in Sickle Cell Disease.
N Engl J Med. 2018 Jul 19;379(3):226-235. doi: 10.1056/NEJMoa1715971.
10
Identification of patients with hemoglobin SS/Sβ thalassemia disease and pain crises within electronic health records.
Blood Adv. 2018 Jun 12;2(11):1172-1179. doi: 10.1182/bloodadvances.2018017541.
Zotero 插件